Sampre Nutrition (530617)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter reported net profit of ₹1 Cr on sales of ₹7 Cr, showing some recent earning power.
• Sales growth of 32.44% indicates demand traction in packaged foods.
• Piotroski F-Score of 6/9 suggests improving operational and balance-sheet signals.
• Positive book value of ₹3.61 per share avoids the worst bankruptcy risk.
• Small market cap of ₹120 Cr leaves room for a genuine operational recovery to move the needle.

Concerns

• ROE of -18.06% and ROCE of -7.13% show the business currently destroys shareholder capital.
• P/B of 18.56 with P/E of 0.00 makes the valuation dependent on future perfection.
• No dividend and no disclosed debt/equity data limit transparency and reward for shareholders.
• Profit growth of 222% likely comes from a low or loss-making base, so the last single quarter is not enough evidence.

AI Analysis

Let me look at this the way I look at any business: what does the company own, what does it earn, and what am I paying? Sampre Nutrition sells at ₹67, giving a market cap of ₹120 crore. Against that, book value is only ₹3.61 per share. Paying 18.56 times book for a company whose return on equity is -18.06% and return on capital -7.13% is not value investing; it is speculation. The latest quarter shows sales of ₹7 crore and net profit of ₹1 crore, and the reported profit growth of 222% sounds exciting. But one quarter does not create a track record. The P/E of 0.00 and negative ROE tell me earnings are still not reliable, and the trailing fundamentals show capital being destroyed, not compounded. Graham would say price is what you pay, value is what you get. Sales growth of 32.44% is interesting, but growth with negative returns on capital is often a trap. It can consume cash, not create it. The Piotroski F-Score of 6/9 is the only mildly constructive signal, suggesting some balance-sheet and efficiency improvements. But debt-to-equity is not available, dividend yield is zero, and the FairStock score is insufficient data. The stock sits at its 52-week high of ₹67, meaning Mr Market is already pricing in a successful turnaround. As a value investor, I cannot rely on hope and momentum. I need consistent earnings, honest disclosure, and a margin of safety. At this price, with this book value and negative returns, Sampre Nutrition remains a speculative turnaround story—not a proven compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer